Spectral AI Outlines U.S. Regulatory Pathway for DeepView® System for Burn Indication
- DALLAS, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today provided an outline of its regulatory pathway strategy to enter the U.S. market with its flagship DeepView® System for burn indication (“DeepView AI®-Burn”).
- 09/17/2024
|
Spectral AI highlights potential of its wound analysis device to bridge burn care gaps
- Spectral AI Inc (NASDAQ:MDAI) has highlighted how its DeepView System has been designed to broaden equity in burn care access and optimize healthcare resources following the release of a new report from the American Burn Association (ABA) which noted physical and economic barriers to burn care specialists. The report, published in the Journal of Burn Care & Research January/February 2024, spotlighted the uneven distribution of ABA-verified burn centers across the United States, particularly impacting rural and pediatric patients.
- 09/10/2024
|
American Burn Association Study Highlights Inequities in Access to Specialized Burn Care
- Spectral AI's DeepView® System Designed to Provide Equity in Burn Care Access While Optimizing Healthcare Resources Spectral AI's DeepView® System Designed to Provide Equity in Burn Care Access While Optimizing Healthcare Resources
- 09/10/2024
|
Spectral AI secures government funding to advance battlefield wound assessment device
- Spectral AI Inc (NASDAQ:MDAI) announced that it has been awarded more than $850,000 from the Medical Technology Enterprise Consortium (MTEC), a biomedical group collaborating with the US Army Medical Material Development Activity, to support the ongoing development of its DeepView SnapShot M. Spectral AI's DeepView SnapShot M is a handheld predictive wound healing device targeting battlefield applications based on its AI-driven DeepView System Platform, which uses multispectral imaging trained against a database of more than 340 billion clinically validated data points to assess a burn wound's healing potential before other medical intervention.
- 09/05/2024
|
Spectral AI Awarded Additional Funding from Medical Technology Enterprise Consortium to Support Ongoing Development of DeepView SnapShot M®
- DALLAS, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has received a new award of over $850,000 from the Medical Technology Enterprise Consortium (“MTEC”).
- 09/05/2024
|
Spectral AI to Participate in Upcoming Investor Conferences
- DALLAS, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Peter M. Carlson, Chief Executive Officer, and Vince Capone, Chief Financial Officer, are scheduled to participate in the following investor conferences in New York City:
- 08/28/2024
|
Spectral AI completes burn center enrollment early for pivotal study
- Spectral AI Inc (NASDAQ:MDAI) announced that it has completed the enrollment of adult and pediatric patients at US burn centers for its pivotal study designed to validate the AI algorithm used by its DeepView system for the burn indication. The company said the data collected from these burn center patients will be used to pursue a De Novo classification from the US Food and Drug Administration (FDA) for the use of the DeepView System in burn centers.
- 08/27/2024
|
Spectral AI Completes Burn Center Enrollment for U.S. Burn Pivotal Study
- Milestone Achievement Advances Commercialization Timeline for DeepView™ System for Burn Indication Milestone Achievement Advances Commercialization Timeline for DeepView™ System for Burn Indication
- 08/27/2024
|
Spectral AI to present data from ongoing pivotal burn study at conference
- Spectral AI Inc (NASDAQ:MDAI) announced that its chief medical consultant Dr Jeffrey Carter will present data from its ongoing multicenter study evaluating its DeepView System for burns at an upcoming conference. The DeepView System leverages non-invasive multispectral imaging technology and proprietary AI to detect non-healing areas of a wound following a burn injury.
- 08/19/2024
|
Spectral AI Announces Podium Presentation at BBA / ISBI Joint Conference Assessing Burn Wound Severity Using Multispectral Imaging and Artificial Intelligence
- DALLAS, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Dr. Jeffrey Carter will present data from an ongoing prospective multicenter study analyzing the use of Spectral AI's DeepView™ System, which utilizes non-invasive multispectral imaging technology and proprietary AI, to detect non-healing areas of a wound following thermal (burn) injury.
- 08/19/2024
|
Spectral AI, Inc. (MDAI) Q2 2024 Earnings Call Transcript
- Spectral AI, Inc. (NASDAQ:MDAI ) Q2 2024 Results Conference Call August 12, 2024 5:00 PM ET Company Participants Devin Sullivan - Managing Director, The Equity Group, Inc. Peter Carlson - Chief Executive Officer Vince Capone - Chief Financial Officer Jeremiah Sparks - Chief Commercial Officer Conference Call Participants Ryan Zimmerman - BTIG Carl Byrnes - Northland Capital Markets RK Ramakanth - HC Wainwright John Vandermosten - Zacks Operator Good day, and welcome to the Spectral AI Inc. Second Quarter 2024 Financial Results Conference Call. All participants will be in a listen-only mode.
- 08/12/2024
|
Spectral AI grows revenue, advances DeepView System for burns in Q2
- Spectral AI Inc (NASDAQ:MDAI) reported a 76% year-over-year jump in revenue for the second quarter as it advanced its AI-driven DeepView System for the burn indication. The company said its Q2 research and development revenue was $7.5 million up from $4.3 million due to increased activity under its Project BioShield contract with BARDA for the advanced development of the DeepView System.
- 08/12/2024
|
Spectral AI Announces 2024 Second Quarter Financial Results
- Second Quarter Revenue Totals $7.5 Million Total Enrollment Exceeds 85% for Burn Center Pivotal U.S. Clinical Trial Q2 2024 Overview Research & Development Revenue of $7.5 Million Cash Position of $6.9 Million On Track to Generate First Commercial Revenues in the U.K. Later this Year Burn Pivotal Study Nearing Completion Paving the Way for U.S. FDA Submission in Early 2025 Announced Collaboration with PolyNovo Ltd. Providing Introduction to Australian Market Continued Progress in Handheld Burn Wound Diagnostic Technology Added to Russell Microcap® Index effective July 1, 2024 DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the second quarter ended June 30, 2024 (“Q2 2024”) and provided an update on its ongoing business activities.
- 08/12/2024
|
Spectral AI advances handheld burn assessment device for military use
- Spectral AI Inc (NASDAQ:MDAI) announced it continues to advance the development of the DeepView SnapShot M, a handheld diagnostic tool for battlefield burn assessments leveraging its AI-driven DeepView System platform. The company highlighted that the DeepView SnapShot M has been designed to be part of the battlefield triage process by providing a fast and accurate assessment of burn wounds.
- 07/31/2024
|
Spectral AI Announces Continuing Progress in Development of Handheld DeepView SnapShot M® for Military Field Use
- Poster Presentation at 2024 Military Health System Research Symposium Poster Presentation at 2024 Military Health System Research Symposium
- 07/31/2024
|
Spectral AI Schedules 2024 Second Quarter Financial Results and Conference Call
- DALLAS, July 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the second quarter ended June 30, 2024 on Monday, August 12, 2024 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results.
- 07/29/2024
|
Spectral AI expands patent portfolio, bolstering AI-driven wound care platform
- Spectral AI Inc (NASDAQ:MDAI) announced a 30% increase in its patent portfolio, enhancing the protection of its proprietary DeepView System wound assessment platform. The total number of patents granted to the company rose to 26, up from 20 at the end of the 2023 calendar year.
- 07/24/2024
|
Spectral AI Announces Total U.S. and International Patent Portfolio Now Stands at 26 Granted Patents and 38 Pending Applications in Support of its AI-Driven DeepView System
- DALLAS, July 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced a 30% increase in its patent portfolio that strengthens and protects its proprietary, AI-driven DeepView System wound assessment platform.
- 07/24/2024
|
Spectral AI adds three new clinical sites to pivotal burn study
- Spectral AI Inc (NASDAQ:MDAI) announced it has added three new US trial sites to its 2024 Burn Pivotal Study, bringing the total number of sites, including burn centers and emergency departments, to 16. The Medical Center Burn Center at Texas Tech University Health Sciences Center led by principal investigator Dr Alan Pang; Tampa General Hospital Burn Center led by principal investigator Dr Jared Troy; and the University of South Alabama Health Emergency Department led by Andrew Bright have been added to the study, the Dallas-based predictive AI company said on Tuesday.
- 07/23/2024
|
Spectral AI Adds Three New Clinical Trial Sites To Expedite Emergency Department Patient Enrollment
- DALLAS, July 23, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has added three new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study: University Medical Center (UMC) Burn Center at Texas Tech University Health Sciences Center led by principal investigator Alan Pang, M.D., Tampa General Hospital Burn Center led by principal investigator Jared Troy, M.D., and University of South Alabama (USA) Health Emergency Department led by Andrew Bright, D.O.
- 07/23/2024
|
Spectral AI highlights concerns over stock manipulation
- Spectral AI Inc (NASDAQ:MDAI) has updated stakeholders on its efforts to address potential market manipulation involving its common stock, primarily through naked short selling. The AI-driven medical diagnostics company told shareholders that it is continuing to support an ongoing naked short selling inquiry led by Erich Spangenberg, a board member and the company's largest shareholder.
- 07/15/2024
|
Spectral AI works with market leader on initial steps in Australia
- Spectral AI Inc (NASDAQ:MDAI) said it will be assisted by a leading medical device company and burn wound therapy company in its application and potential deployment of its DeepView System for burn indication in Australia. Under a collaboration agreement signed between the two companies, Melbourne-based PolyNovo Ltd will help with Spectral AI's near-term goal of deploying up to two of the systems at the Royal Adelaide Hospital (pictured) and The Alfred Hospital in Melbourne.
- 07/08/2024
|
Spectral AI Announces Collaboration with Global Wound Care Company PolyNovo to Introduce DeepView System for Burn Indication to Australian Market
- DALLAS, July 08, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has signed a Memorandum of Understanding (“MOU”) with global medical device company and burn wound therapy leader PolyNovo Limited (“PolyNovo”) under which the companies will collaborate to assist Spectral AI in a potential limited deployment of its DeepView System for burn indication in Australia.
- 07/08/2024
|
Spectral AI adds two clinical trial sites to pivotal burn study
- Spectral AI Inc (NASDAQ:MDAI) announced that it has added two US clinical trial sites to its 2024 burn study, the University of California San Diego and the University of Utah. The medical diagnostics company said the addition of these new locations expands the total number of US clinical trial sites to 14.
- 07/03/2024
|
Spectral AI Expands Clinical Trial Sites for Pivotal U.S. Burn Study
- DALLAS, July 03, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has added two new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study: the University of California San Diego and the University of Utah.
- 07/03/2024
|
Spectral AI achieves full pediatric enrollment in pivotal burn study
- Spectral AI Inc (NASDAQ:MDAI), a company specializing in AI-driven medical diagnostics, has announced the completion of pediatric patient enrollment for its 2024 pivotal study. The study aims to validate the AI algorithm of its DeepView System for burn indications and is set to conclude in the fourth quarter of 2024.
- 07/02/2024
|
Spectral AI Achieves 100% Pediatric Enrollment in Burn Centers for Pivotal U.S. Burn Study
- DALLAS, July 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has achieved 100% pediatric patient enrollment at burn centers for its 2024 pivotal study designed to validate the AI-driven algorithm used by its DeepView™ System for its burn indication.
- 07/02/2024
|
Spectral AI joins Russell Microcap Index
- Spectral AI Inc (NASDAQ:MDAI), the wound care diagnostics specialist, has been included in the Russell Microcap Index following the annual Russell Reconstitution, which took effect after the market close on June 28, 2024. The reconstituted Russell Microcap Index will commence trading on July 1, 2024.
- 07/01/2024
|
Spectral AI Joins Russell Microcap® Index
- DALLAS, July 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its inclusion in the Russell Microcap Index following the annual Russell Reconstitution, which took effect after the market close on June 28, 2024. The reconstituted Russell Microcap Index will commence trading on July 1, 2024.
- 07/01/2024
|
Spectral AI near full enrollment of pediatric patients in burn study
- Spectral AI Inc (NASDAQ:MDAI) announced it surpassed 90% of its enrollment target for pediatric patients at burn centers for its late-stage study evaluating its AI-driven DeepView System. The company's DeepView System utilizes proprietary multispectral imaging to distinguish between healthy and damaged tissue and can be used upon a child's arrival at the emergency department or burn center to provide immediate and accurate wound assessments in support of timely clinical decision-making for burn injuries.
- 06/27/2024
|
Spectral AI Surpasses 90% of Pediatric Enrollment Target in Burn Centers for Pivotal U.S. Burn Study
- DALLAS, June 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has surpassed 90% of the enrollment target for pediatric patients at burn centers for its 2024 pivotal study designed to validate the AI-driven algorithm used by its DeepView™ System for its burn indication.
- 06/27/2024
|
Spectral AI supports naked short selling probe
- Spectral AI Inc (NASDAQ:MDAI) told investors that it has provided support to Nasdaq and the state securities authorities in Florida, Louisiana and Texas to bring their attention to the potential market manipulation of the company's stock, primarily in the form of naked short selling. The company said the inquiry is being led by Erich Spangenberg, a member of its board of directors and its largest shareholder.
- 06/24/2024
|
Spectral AI to Participate in the Northland Capital Markets Virtual Growth Conference
- DALLAS, June 17, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will participate in the Northland Capital Markets Virtual Growth Conference on Tuesday, June 25, 2024.
- 06/17/2024
|
Spectral AI reaches enrollment milestone for pivotal DeepView System study at US burn centers
- Spectral AI Inc (NASDAQ:MDAI) announced that it has achieved 50% clinical trial site enrollment for its pivotal Deepview System study. The DeepView System's image processing algorithm uses multispectral imaging, which has been trained on a proprietary database of more than 340 billion data points, to aid healthcare providers in assessing the healing potential of a burn wound.
- 06/06/2024
|
Spectral AI Reaches 50% Enrollment at Burn Centers for U.S. Pivotal Burn Study
- DALLAS, June 06, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has achieved 50% clinical trial site enrollment at burn centers for its 2024 pivotal study designed to validate the algorithm used by its DeepView™ System for burn indication. This pivotal study, which is targeting enrollment of 240 patients, including both adult and pediatric subjects at multiple burn centers and emergency departments across the U.S., is expected to be the final clinical trial before seeking FDA approval in 2025.
- 06/06/2024
|
Spectral AI to join Russell Microcap Index
- Spectral AI Inc (NASDAQ:MDAI) an artificial intelligence company specializing in medical diagnostics for wound care, is set to join the Russell Microcap Index. The Russell Microcap Index is designed to represent the microcap segment of the U.S.
- 05/29/2024
|
Spectral AI Set to Join Russell Microcap® Index
- DALLAS, May 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective following the closing of US equity markets on Friday, June 28, 2024 according to a preliminary list of additions posted Friday, May 24, 2024.
- 05/29/2024
|
Spectral AI to Participate in Benzinga's “AI Unleashed: Exploring the Possibilities” Virtual Event
- DALLAS, May 28, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Peter M. Carlson, Chief Executive Officer of Spectral AI, is scheduled to participate in a fireside chat at Benzinga's “AI Unleashed: Exploring the Possibilities” virtual event, taking place on May 30, 2024.
- 05/28/2024
|
Spectral AI executives acquire shares as company advances AI wound care technology
- Spectral AI Inc (NASDAQ:MDAI) announced that several of its officers and directors acquired approximately 113,000 shares of Spectral AI common stock in open market transactions in May. These transactions were made publicly and not through private arrangements, which can indicate confidence in the company's future prospects by its leadership.
- 05/17/2024
|
Spectral AI Announces Purchases of Over 100,000 Shares by Insiders
- DALLAS, May 17, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that several of the Company's officers and directors acquired approximately 113,000 shares of Spectral AI common stock in open market transactions on May 10, 2024 and May 15, 2024.
- 05/17/2024
|
Spectral AI Announces Voting Results from 2024 Annual Meeting of Stockholders and the Appointment of Erich Spangenberg to the Board of Directors
- DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2024 Annual Meeting of Stockholders held on May 14, 2024 (the “AGM”). At the AGM, stockholders overwhelmingly approved each of the four proposals set forth by the Company.
- 05/15/2024
|
Spectral AI, Inc. (MDAI) Q1 2024 Earnings Call Transcript
- Spectral AI, Inc. (NASDAQ:MDAI ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Devin Sullivan - Managing Director, The Equity Group, Inc. Peter Carlson - CEO Vincent Capone - CFO and General Counsel Conference Call Participants Ramakanth Swayampakula - H.C. Wainwright John Vandermosten - Zacks Christopher Recouso - Partner Cap Group Operator Good day, and welcome to the Spectral AI First Quarter 2024 Financial Results Conference Call.
- 05/11/2024
|
Spectral AI hails progress towards first sales and pre-FDA clinical trial
- Spectral AI Inc (NASDAQ:MDAI) hailed progress in the first quarter towards first commercial product revenue later this year, along with strengthening of the management team and financial position. The developer of the DeepView wound imaging system reported research & development revenue of $6.3 million for Q1, compared to $5.1 million a year ago, as it carried out an increased level of activity under the contracts with the US Biomedical Advanced Research & Development Authority (BARDA).
- 05/08/2024
|
Spectral AI Announces 2024 First Quarter Financial Results
- Q1 Overview Research & Development Revenue of $6.3 Million Improved Capital Structure Reflected in Cash of $10.2 Million DeepView AI®-Burn Devices Deployed in UK; Expect Commercial Revenue in 2H 2024 Additional Regulatory Submissions in US and UK for DeepView™ System Expected in 2024 and 2025 DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2024 (“Q1 2024”) and provided an update on its ongoing business activities. “During the first quarter we continued to execute against our strategic priorities resulting in significant accomplishments across the enterprise,” said Peter M.
- 05/07/2024
|
Spectral AI to Participate at the Sidoti Micro-Cap Virtual Investor Conference
- DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that management is scheduled to present and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Investor Conference, taking place on May 8-9, 2024.
- 05/02/2024
|
Spectral AI receives TMAC Quality Achievement Award for wound care technology
- Spectral AI Inc (NASDAQ:MDAI) announced it has been awarded the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center (TMAC) for its UK Conformity Assessed (UKCA) Mark Attainment. The Dallas-based company is advancing its DeepView technology, a predictive device that allows clinicians to assess a wound and provide faster and more accurate treatment insights.
- 05/01/2024
|
Spectral AI Awarded Quality Achievement Award from the Texas Manufacturer Assistance Center
- DALLAS, April 30, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the company received the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center (TMAC) for their UKCA Mark Attainment.
- 04/30/2024
|
Spectral AI Schedules 2024 First Quarter Financial Results and Conference Call
- DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results.
- 04/24/2024
|
Spectral AI appoints Erich Spangenberg as CEO of Spectral IP
- Spectral AI Inc (NASDAQ:MDAI) has appointed Erich Spangenberg to lead its health care IP-focused subsidiary, Spectral IP. Spangenberg, Spectral AI's largest shareholder, brings decades of experience in global IP investment and monetization.
- 04/24/2024
|
Spectral AI Names Erich Spangenberg CEO of its IP Focused Subsidiary and Explores Potential Spin-Off of that Subsidiary
- Spangenberg brings significant IP monetization experience and the potential to unlock additional value for Spectral AI shareholders Spangenberg brings significant IP monetization experience and the potential to unlock additional value for Spectral AI shareholders
- 04/24/2024
|
Spectral AI Appoints Jeremiah Sparks as Chief Commercialization Officer
- Experienced Burn Industry Executive Champions Pivot to Commercialization Experienced Burn Industry Executive Champions Pivot to Commercialization
- 04/01/2024
|
Spectral AI, Inc. (MDAI) Q4 2023 Earnings Call Transcript
- Spectral AI, Inc. (MDAI) Q4 2023 Earnings Call Transcript
- 03/27/2024
|
Spectral AI reiterates 2024 R&D revenue guidance which excludes DeepView commercialization contributions
- Spectral AI Inc (NASDAQ:MDAI) has reiterated its 2024 research and development (R&D) revenue guidance of $28 million which notably does not include expected contributions from the commercialization of its DeepView burn wound care system in the United Kingdom. The predictive AI company focused on medical diagnostics for improved wound care achieved revenue of $18.1 million for 2023, it reported after Wednesday's closing bell.
- 03/27/2024
|
Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results
- 2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024
- 03/27/2024
|
Spectral AI announces up to $30M equity funding agreement with long-time investor
- Spectral AI Inc (NASDAQ:MDAI) announced that it has entered into a fixed-price prepaid advance and standby equity purchase agreement with a longstanding investor. The company said that the total capacity under the agreement is $30 million which consists of a prepaid advance of $12.5 million.
- 03/20/2024
|
Spectral AI Secures Access to $12.5 Million of New Equity Capital
- Issuance of Convertible Instrument Balances Certainty, Timing, and Execution Capital Supports Strategic Imperatives and Commercialization Initiatives
- 03/20/2024
|
Spectral AI secures $1M investment in AI IP subsidiary
- Spectral AI Inc (NASDAQ:MDAI) announced that it has received a $1 million investment from an affiliate of its largest shareholder into its newly created subsidiary Spectral IP. Spectral IP will be focused on developing intellectual property for the broader AI ecosystem through acquisitions, strategic partnerships, and collaborations with AI technology providers, healthcare institutions, and research organizations.
- 03/19/2024
|
Spectral AI Schedules 2023 Fourth Quarter and Full Year Financial Results and Conference Call
- DALLAS, March 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, March 27, 2024 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results.
- 03/13/2024
|
Why Is Spectral AI (MDAI) Stock Up 15% Today?
- Spectral AI (NASDAQ: MDAI ) stock is on the rise Tuesday after the artificial intelligence ( AI ) company announced a $500,000 government contract for its wound imaging technology. According to a press release from Spectral AI, it's teaming up with the Defense Health Agency (DHA) and the US Army Medical Material Development Activity (USAMMDA).
- 03/12/2024
|
How Much Could New Army Contract Boost This AI Stock?
- Leading medical diagnostics artificial intelligence company Spectral AI Inc. (NASDAQ: MDAI) announced on Monday that it had secured a new contract with the Defense Health Agency and the U.S.
- 03/12/2024
|
Spectral AI wins US government contract to develop handheld DeepView wound imaging system
- Spectral AI Inc (NASDAQ:MDAI) announced that it has secured a contract with the Defense Health Agency (DHA) and the US Army Medical Material Development Activity (USAMMDA) to support the development of the handheld version of its DeepView Wound Imaging System, DeepView SnapShot M, which is targeting battlefield use. The company said the contract was valued at more than $500,000 and brings the total awarded to advancing the DeepView SnapShot M to more than $6 million.
- 03/12/2024
|
Spectral AI to advance AI-driven healthcare solutions through new subsidiary
- Spectral AI Inc (NASDAQ:MDAI) announced that it has created a wholly-owned subsidiary dedicated to advancing intellectual property (IP) related to the broader AI ecosystem, with a focus on healthcare. “After conducting a comprehensive review of our IP portfolio, we are confident that Spectral AI has effectively safeguarded its current and anticipated future product offerings through a combination of patents and trade secrets,” Spectral AI CEO Pete Carlson said in a statement.
- 03/07/2024
|
Spectral AI to Participate in Upcoming Investor Conferences
- DALLAS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that management is scheduled to participate in the following investor conferences:
- 02/28/2024
|
Spectral AI sees revenue starting in 2024 from DeepView burn diagnosis system after securing UKCA Authorization
- Spectral AI Inc (NASDAQ:MDAI) announced that its predictive software DeepView AI-Burn has received the final stage of the UK Conformity Assessed (UKCA) authorization for aiding in burn wound diagnosis in the United Kingdom. The medical devices firm said it expects to soon deploy six of its DeepView devices in the UK for customer evaluation which is expected to generate revenue starting in the second half of 2024.
- 02/22/2024
|
Forget Nvidia: AI stocks with significant growth potential to watch
- All eyes are on NVIDIA Corp (NASDAQ:NVDA, ETR:NVD) this week ahead of its earnings report due Wednesday as the chipmaker targets another quarterly revenue record of $20 billion. The company, which makes semiconductor chips for AI applications, has seen its shares soar by about 230% in the last year, driven by investor enthusiasm for all things AI.
- 02/20/2024
|
Spectral AI founder and ex-boss returns as director
- Spectral AI Inc (NASDAQ:MDAI), the medical technology company, appointed founder and former boss Michael DiMaio as a non-executive director last week, replacing the position left by Michael Murphy. DiMaio served as the company's chief executive officer and chairman between 2011 and 2020, with all disputes surrounding his exit having been “amicably resolved”.
- 02/12/2024
|
Spectral AI closing in on commercial revenue from DeepView system
- Spectral AI Inc (NASDAQ:MDAI) has told investors that interim results of ongoing clinical trials designed to validate its DeepView System will be “promising”. This includes tests of the medical imaging company's DeepView system in offering wound healing assessments in burn victims and those with diabetic foot ulcers.
- 02/05/2024
|
Spectral AI moves towards commercialization of burn care predictive software with UKCA mark application
- Spectral AI Inc (NASDAQ:MDAI) subsidiary Spectral MD announced that it has submitted an application in the United Kingdom for its predictive software DeepView AI-Burn to be registered as UK Conformity Assessed (UKCA) for burn use in the country. The company highlighted that the software DeepView AI-Burn integrates with its UKCA-granted application for its imaging device DeepViewSnapShot.
- 01/29/2024
|
Spectral AI initiates pivotal study for DeepView AI in burn care
- Spectral AI Inc (NASDAQ:MDAI) said it has started enrollment for a pivotal study of DeepView AI, utilizing its proprietary imaging technology for burn size and healing assessment. The study is a crucial step towards obtaining FDA marketing authorization for burn indication in 2025, the Dallas-based company said in a statement.
- 01/11/2024
|
Spectral AI taps experienced exec as new CFO
- Spectral AI Inc (NASDAQ:MDAI) announced that it has appointed Peter Carlson as its chief financial officer. Carlson has previously served as CFO at MiMedx Group, chief operating officer at Brighthouse Financial, and chief accounting officer at MetLife.
- 12/19/2023
|
Spectral AI appoints IP veteran Erich Spangenberg as Executive Committee chairman
- Spectral AI Inc (NASDAQ:MDAI) has announced the appointment of Erich Spangenberg, the company's largest shareholder, to its board of directors, who will serve as Executive Committee chairman as well as on the Nominating and Corporate Governance Committee. The predictive AI company focused on medical diagnostics said Spangenberg has 40 years of experience as an entrepreneur, investor, investment banker, and attorney, as is the founder and managing director of Sauvegarder Investment Management, a multi-strategy investment firm dedicated to IP-related financings.
- 11/27/2023
|
Spectral AI wraps up “extraordinary” 3Q amid progress with DeepView System
- Spectral AI Inc (NASDAQ:MDAI) told investors it had an “extraordinary” third quarter, highlighted by its listing on Nasdaq and the continued progress made with its DeepView System Wound Healing Assessment Technology. Releasing results for the quarter, Spectral AI CEO Wensheng Fan noted the company also received the largest contract in its history: a $149 million award from the US government to advance the AI-driven DeepView System for burn wound assessment.
- 11/14/2023
|
Spectral AI Schedules 2023 Third Quarter Financial Results and Conference Call
- DALLAS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the third quarter ended September 30, 2023 on Monday, November 13, 2023 after the close of the stock market. The Company will host a conference call on Tuesday, November 14, 2023 at 9:00 am Eastern Time to discuss the results.
- 11/01/2023
|
Spectral AI taps Paul Chadwick to lead DeepView global expansion
- Spectral AI Inc (NASDAQ:MDAI) is beefing up its executive team in the UK with the addition of Prof Paul Chadwick. Chadwick, a distinguished clinical scientist and key opinion leader in wound care, will lead the international expansion of Spectral AI's DeepView wound imaging technology across the United Kingdom, Europe, the Middle East, and Africa.
- 10/24/2023
|
Spectral AI provides positive 2023 and 2024 revenue guidance
- Spectral AI Inc (NASDAQ:MDAI) has announced that its full-year 2023 revenue is expected to approximately $17.4 million, while its revenue in 2024 is expected to be about $28.0 million. The predictive AI company said it recently revealed the largest contract in its history, an award from the US Government valued at over $149.0 million, which brings its total US Government awards since 2019 to over $246.0 million.
- 10/23/2023
|
Spectral AI shares surge as wound imaging device wins regulatory approvals in US and UK
- Spectral AI Inc (NASDAQ:MDAI) shares surged in pre-market trade after the company announced that its DeepView SnapShot Wound Imaging System is now United Kingdom Conformity Assessed (UKCA)-marked for use in the UK and it has achieved Class 1 medical device classification from the United States Food and Drug Administration (FDA). The company's DeepView SnapShot is a patented, universal imaging platform that uses predictive artificial intelligence (AI) software to assist clinicians in making quicker and more accurate decisions in wound care.
- 10/19/2023
|
Spectral AI expands diabetic foot ulcer study to additional clinical sites
- Spectral AI Inc (NASDAQ:MDAI) announced it has added seven clinical sites to its multi-centre study of its DeepView Wound Imaging System for diabetic foot ulcers. The company said that its proprietary technology uses multi-spectral imaging and artificial intelligence (AI) to provide clinicians with a healing assessment of diabetic foot ulcers, leading to more accurate and timely diagnosis and therapeutic intervention.
- 10/16/2023
|
Are Penny Stocks Worth It? 4 To Watch With Big News
- Penny stocks, defined as stocks trading under $5 per share, are known for their volatility and potential for significant returns. However, the low price of these stocks also makes them susceptible to dramatic price swings based on company-specific and industry news events.
- 10/04/2023
|
